ASH 2022 | ENERGY: Phase II/III study of nipocalimab in patients with wAIHA
Irina Murakhovskaya, MD, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, comments on the design of the ENERGY study (NCT04119050), a Phase II/III trial of nipocalimab, a neonatal Fc receptor (FcRn) blocker, in patients with warm autoimmune hemolytic anemia (wAIHA), explaining the mechanism of action of this drug. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Research Funding; Alexion: Research Funding; Annexon: Research Funding; Kezar: Research Funding; Rigel: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.
